<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01759238</url>
  </required_header>
  <id_info>
    <org_study_id>OLGA</org_study_id>
    <secondary_id>2011-005296-16</secondary_id>
    <nct_id>NCT01759238</nct_id>
  </id_info>
  <brief_title>Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer</brief_title>
  <acronym>OLGA</acronym>
  <official_title>Capecitabine and Bevacizumab With Radiotherapy After 3-6 Months Chemotherapy for Patients With Oligometastatic Colorectal Cancer (OLGA Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study tries to evaluate the role of chemoradiation with capecitabine and bevacizumab in&#xD;
      oligometastatic patients neither being progressive nor resectable after chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Combining chemoradiation with an antiangiogenic agent has a strong biological rationale, and&#xD;
      preclinical studies consistently show an increase in radiosensitization with combined&#xD;
      treatment. It is well described that hypoxia or HIF-1 expression is associated with a lower&#xD;
      radiation response and progression in solid tumors. Radiation itself induces transient tumor&#xD;
      hypoxia, which in turn stimulates VEGF production and VEGFR-2 expression what may also serve&#xD;
      as a paracrine proliferative stimulus that promotes out-of-field growth. The combination of&#xD;
      radiotherapy with an antiangiogenic agent (e.g. bevacizumab) thus offers the potential to&#xD;
      enhance the effect of radiation, and avoid further spread of disease. Furthermore, targeting&#xD;
      tumor vasculature improves the delivery of cytotoxic drugs (e.g. capecitabine) leading to&#xD;
      increased efficacy of chemoradiation. Combination with cytotoxic drugs could additionally&#xD;
      limit treatment-induced hypoxia (Senan and Smit 2007; Mazeron, Anderson et al. 2011).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual&#xD;
  </why_stopped>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival rate</measure>
    <time_frame>12 months</time_frame>
    <description>Progression free survival rate at 12 months after start of induction treatment (PFSR@12)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP) in 2 cohorts</measure>
    <time_frame>24 months</time_frame>
    <description>Time to progression (TTP) in 2 cohorts:&#xD;
regards only progression within (TTPir) and&#xD;
in- and outside irradiated areas (&quot;overall&quot; TTP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Efficacy of the investigational therapy shown by the Overall Response Rate (CR and PR) according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL)</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of life using the EORTC QLQ-C30 and the module CR29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic and predictive value of PET scan</measure>
    <time_frame>at baseline and 2 months after chemoradiation</time_frame>
    <description>Prognostic and predictive value of PET scan at baseline and at 2 months after chemoradiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>12 months</time_frame>
    <description>Number of adverse events, according to NCI CTCAE v4.0)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Metastases</condition>
  <arm_group>
    <arm_group_label>Chemoradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemoradiation with different radiotherapy regimes (depending on location and size of irradiated lesions; e.g. conventional radiotherapy with a total dose of 35 Gy, delivered in 2.5Gy fractions for 14 days or intensity-modulated and image-guided radiotherapy with a total dose of 40 Gy, delivered in 4.0 Gy fractions for 10 days or 3-8 fractions with 8-15 Gy) combined with bevacizumab (7.5mg/kg day 1) and capecitabine (825mg/m2 bid on day 1-5, 8-12 and 15-19)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>825mg/m2 per os bid</description>
    <arm_group_label>Chemoradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>7.5 mg/kg</description>
    <arm_group_label>Chemoradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>(conventional or intensity-modulated and image-guided radiotherapy)</description>
    <arm_group_label>Chemoradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with histologically confirmed diagnosis of stage IV (UICC) colorectal cancer&#xD;
&#xD;
          2. Oligometastatic disease, defined as at least one measureable lesion with size &gt; 1cm&#xD;
             (RECIST v1.1) to a maximum of 3 sites and 5 lesions suitable for radiotherapy&#xD;
             according to the dose constraints for normal tissue&#xD;
&#xD;
          3. Patients being neither progressive nor resectable after 3-6 months of first line&#xD;
             chemotherapy (combination chemotherapy, at least chemo-doublet) with bevacizumab&#xD;
&#xD;
          4. maximum treatment interruption after induction therapy of 6 weeks&#xD;
&#xD;
          5. ECOG performance status ≤ 1&#xD;
&#xD;
          6. Life expectancy &gt; 3 months&#xD;
&#xD;
          7. Age ≥ 18 years&#xD;
&#xD;
          8. Haematologic function: ANC ≥ 1.5 x 109/L, platelets ≥ 75 x109/L&#xD;
&#xD;
          9. INR &lt; 1.5 within 7 days prior to starting study treatment. aPTT &lt; 1.5 ULN within 7&#xD;
             days prior to starting study treatment&#xD;
&#xD;
         10. adequate liver function as measured by serum transaminases (AST &amp; ALT) ≤ 5 x ULN and a&#xD;
             total bilirubin ≤1.5 x ULN&#xD;
&#xD;
         11. adequate renal function: serum creatinine ≤ 1.5 x ULN&#xD;
&#xD;
         12. signed, written informed consent&#xD;
&#xD;
         13. ability to swallow tablets&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. treatment with any other investigational agent, or participation in another clinical&#xD;
             trial within 30 days prior to entering this study&#xD;
&#xD;
          2. prior radiotherapy for metastatic lesions (prior radiotherapy for primary tumor&#xD;
             allowed if followed by complete resection and no sign for local recurrence at the time&#xD;
             of enrolment)&#xD;
&#xD;
          3. Pre history or evidence upon physical/neurological examination of CNS disease&#xD;
             (unrelated to cancer) (unless adequately treated with standard medical therapy) e.g.&#xD;
             uncontrolled seizures&#xD;
&#xD;
          4. fertile women (&lt; 2 years after last menstruation) and women of childbearing potential&#xD;
             unwilling or unable to use effective means of contraception (oral contraceptives,&#xD;
             intrauterine contraceptive device, barrier method of contraception in conjunction with&#xD;
             spermicidal gel or surgically sterile)&#xD;
&#xD;
          5. pregnancy or lactation&#xD;
&#xD;
          6. Positive serum pregnancy test within 7 days of starting study treatment in&#xD;
             pre-menopausal women and women &lt; 2 years after the onset of menopause. Note: a&#xD;
             negative test has to be reconfirmed by a urine test, should the 7-day window be&#xD;
             exceeded.&#xD;
&#xD;
          7. Past or current history (within the last 2 years prior to treatment start) of other&#xD;
             malignancies except metastatic colorectal cancer (patients with curatively treated&#xD;
             basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix are&#xD;
             eligible).&#xD;
&#xD;
          8. Known DPD-insufficiency&#xD;
&#xD;
          9. Active inflammatory bowel disease or other bowel disease causing chronic diarrhea&#xD;
             (defined as &gt; 4 loose stools per day)&#xD;
&#xD;
         10. Serious, non-healing wound, ulcer or bone fracture.&#xD;
&#xD;
         11. Evidence of bleeding diathesis or coagulopathy.&#xD;
&#xD;
         12. Urine dipstick for proteinuria &gt;2+. If urine dipstick is 2+, 24-hour urine must&#xD;
             demonstrate 1 g of protein in 24 hours for patient to be eligible.&#xD;
&#xD;
         13. Major surgical procedure, open biopsy or significant traumatic injury within 28 days&#xD;
             prior to first treatment with study medication.&#xD;
&#xD;
         14. Clinically significant cardiovascular disease, for example CVA, myocardial infarction&#xD;
             (£ 12 months before treatment start), unstable angina pectoris, NYHA Class II CHF,&#xD;
             arrhythmia requiring medication, or uncontrolled hypertension.&#xD;
&#xD;
         15. Evidence of any other disease, metabolic dysfunction, physical examination finding or&#xD;
             laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use of an investigational drug or puts the patient at high risk&#xD;
             for treatment-related complications.&#xD;
&#xD;
         16. Concomitant therapy with sorivudin or chemical analogues like brivudin&#xD;
&#xD;
         17. Known hypersensitivity or contraindication to the drugs used in the trial (eg:&#xD;
             capecitabine, bevacizumab)&#xD;
&#xD;
         18. Inability or unwillingness to comply with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cordula Petersen, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>December 17, 2012</study_first_submitted>
  <study_first_submitted_qc>January 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2013</study_first_posted>
  <last_update_submitted>February 4, 2015</last_update_submitted>
  <last_update_submitted_qc>February 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>metastases</keyword>
  <keyword>non resectable</keyword>
  <keyword>chemoradiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

